The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma

Lung cancer is the leading cause of cancer deaths; its incidence and mortality is increasing rapidly. Non-small-lung-cancer (NSCLC) accounts for about 85% of all lung carcinomas, and the five-year survival rate is extremely low [1]. With the rapid development of molecular targeted therapy, anaplastic lymphoma kinase (ALK) was proven to be another main oncogene-driven gene after the epidermal growth factor receptor (EGFR). ALK fusions account for approximately 2% –7% of patients with lung adenocarcinoma [2].

Source: Lung Cancer - August 30, 2019 Category: Cancer & Oncology Authors: Tingting Feng, Zhongzhong Chen, Jianjun Gu, Yuxiu Wang, Jun Zhang, Lingfeng Min Source Type: research